Division of Cilag GmbH International/Covagen AG
Latest From Covagen AG
Biopharma financing dropped 22% in Q3 to $5.65 billion. In the largest M&A, Roche bulked up on rare diseases, gaining Esbriet through its $8 billion takeover of InterMune; Sanofi dominated in alliance dealmaking.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
While Valeant prepares for an October court date to resolve Allergan’s attempt to fend off its latest takeover attempt, the acquisitive Canadian specialty firm picked up some dermatology products from Valeo Pharma. Also this week, Cilag acquired Covagen and Vaccinogen raised $80 million for development of OncoVAX.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
- Drug Discovery Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Cilag GmbH International
- Johnson & Johnson
- Senior Management
Julian Bertschinger, PhD, CEO
Dragan Grabulovski, PhD, CSO
Elias Papatheodorou, CBO
- Contact Info
Phone: (49) 44 732 46 60
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.